Galectin Therapeutics
Country
USA
Краткое название
Galectin Therapeutics
Headquarters
4960 Peachtree Industrial Boulevard Suite 240
Members of the board
Peter G. Traber, M.D.,
President, Chief Executive Officer and Chief Medical Officer
Harold H. Shlevin, PhD,
Chief Operating Officer and Corporate Secretary
Eliezer Zomer, Ph.D.,
Executive Vice President, Manufacturing and Product Development
Thomas A. McGauley, CPA,
Acting Chief Financial Officer
Rex Norton,
Executive Director of Regulatory Affairs and Quality Assurance
Stage of the project
Production
Disease
Gastric cancer
Ticker
GALT
Current owners
James C. Czirr,
Executive Chairman of the Board
Gilbert F. Amelio, Ph.D.,
Kevin D. Freeman, CFA,
Arthur R. Greenberg,
Rod D. Martin,
John Mauldin,
Steven Prelack,
Paul Pressler,
Jerald K. Rome,
Marc Rubin, M.D.,
Peter G. Traber, M.D.
Assets
69.5300
Technology
Cell Technologies, Devices, Technologies, Pharmaceuticals, Chemistry